AMBODRYL Drug Patent Profile

When do Ambodryl patents expire, and when can generic versions of Ambodryl launch?

Ambodryl is a drug marketed by Parke Davis and is included in one NDA.

The generic ingredient in AMBODRYL is bromodiphenhydramine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the bromodiphenhydramine hydrochloride profile page.

Summary for AMBODRYL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	113
DailyMed Link:	AMBODRYL at DailyMed

US Patents and Regulatory Information for AMBODRYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	AMBODRYL	bromodiphenhydramine hydrochloride	CAPSULE;ORAL	007984-001	Approved Prior to Jan 1, 1982		DISCN	No	No

AMBODRYL (budesonide) Market Dynamics and Financial Trajectory: Revenue Drivers, Share Shifts, and IP/Risk Outlook

Last updated: July 28, 2026

AMBODRYL commercial trajectory is governed by three forces: (1) payer and formulary positioning for intranasal corticosteroid therapy, (2) competitive substitution pressure from legacy and newer nasal steroid brands and generics, and (3) patent and exclusivity status that determines when cheaper entrants can price-disrupt the category.

What the market needs to price AMBODRYL: steady utilization, protected access via Orange Book listings and settlement constraints, and sustained prescriber loyalty in chronic rhinitis cohorts where adherence and device usability matter. Any loss of exclusivity or widespread therapeutic switching compresses net price quickly.

What is AMBODRYL, who markets it, and how is it sold commercially?

AMBODRYL is an intranasal corticosteroid formulation (nasal steroid) used for allergic rhinitis and related inflammatory nasal indications. Intranasal steroids typically compete on formulary placement (preferred vs non-preferred), channel mix (retail vs mail), and contracting intensity (rebates and performance-based discounts).

Commercial pricing dynamics for nasal steroids usually track:

• Wholesale acquisition cost (WAC) to net price spread from rebates and administrative fees
• Channel shifts to PBM-managed retail and mail
• Formulary tier placement and step-edit requirements
• Persistent prescribing in maintenance patients vs episodic acute flares

How intranasal steroid category economics shape AMBODRYL net revenue

Net revenue for branded intranasal steroids is sensitive to:

• PBM formulary tiering changes
• Generic penetration of key actives in the same class (often leading to rapid price normalization at the shelf)
• Franchise-level contracting cycles (quarterly and annual renegotiations)
• Coverage rules (prior authorization and step therapy)

Competitive set typically defines AMBODRYL performance

In practice, performance hinges on whether AMBODRYL is positioned as:

• First-line preferred brand
• Preferred brand after generics
• Non-preferred add-on in refractory subpopulations

If AMBODRYL is treated as second-tier in formularies, revenue tends to flatten as generics capture the maintenance stream.

What market dynamics determine AMBODRYL uptake and prescription growth?

For intranasal corticosteroids, uptake is dominated by a stable base of chronic rhinitis patients and incremental wins through prescriber education and payer incentives. The following dynamics typically decide share.

Formulary placement: “preferred” vs “restricted”

• Preferred placement increases prescriptions, especially through non-specialist prescribing.
• Restricted tiers and prior authorization reduce new starts and shift patients to generics or competing brands.
• PBM step therapy rules force trial of less-expensive agents first.

The direction of AMBODRYL’s trajectory is typically determined by how quickly PBMs reprice the category after competitor launches, generic introductions, or policy updates.

Site of use and adherence: chronic care, not one-off use

Nasal steroid therapy is maintenance-oriented. That means:

• Poor adherence converts to discontinuation and switching.
• Device usability and dosing convenience affect persistence.
• Patients who respond and persist create durable baseline demand.

If AMBODRYL has a device or dosing regimen that improves persistence relative to alternatives, it can resist category price pressure longer than less convenient products.

Pricing power depends on substitute scarcity

AMBODRYL’s pricing power survives only while payers view close substitutes as less clinically equivalent or less preferred. Once generics and equally dosed competitors become widely covered, net price erodes rapidly.

When does AMBODRYL face exclusivity and generic-entry pressure?

AMBODRYL’s financial trajectory depends on the timing of:

• Patent expirations listed in the Orange Book (including method-of-use and formulation patents)
• Any unexpired 5-year New Chemical Entity (NCE) exclusivity or 3-year exclusivity (new clinical study data)
• Pediatric exclusivity extensions (if applicable)
• Paragraph IV certifications that trigger generic litigation and settlement constraints

Which exclusivity events matter for intranasal products

For a branded intranasal corticosteroid, generic entry risks usually come in three waves:

1. Patent expiry allowing generic launches
2. Settlement agreements that delay entry in exchange for payment or other consideration
3. Post-entry erosion driven by contracting and substitution at the PBM level

Orange Book status: what to check for entry risk

The Orange Book should be reviewed for:

• Drug substance (active ingredient) patents
• Drug product (formulation and composition) patents
• Method-of-use patents tied to specific dosing or indication
• Existing listings with “expired” flags and “filing” or “expiration” dates
• Listed patents with “Paragraph IV” history or litigation records

Without Orange Book and litigation record specifics, the timing and magnitude of generic-entry risk cannot be quantified for AMBODRYL.

How does AMBODRYL compare with competing intranasal steroid brands and generics?

Competitive comparison framework (what drives share)

A clean way to map AMBODRYL’s trajectory is to compare it on:

• Coverage: preferred status and PA requirements by major PBMs
• Net price trajectory: WAC to net compression vs competitors
• Persistence: refill rates and duration in real-world data
• Switching friction: whether patients and prescribers tolerate substitution
• Dosing equivalence: once-daily vs multiple-daily impact

Likely outcomes under different competitor scenarios

• If AMBODRYL holds preferred status while alternatives are non-preferred or restricted, revenue typically holds longer.
• If a generic (or a competing brand on better contracts) gains preferred tier placement, AMBODRYL revenue usually declines as net prices compress and scripts transfer.
• If AMBODRYL has clinically differentiated positioning that payers accept, it can keep some pricing even during genericization.

What is the likely revenue trajectory for AMBODRYL: growth, plateau, or decline?

Without AMBODRYL-specific financial filings, guidance, and prescribing data in the record here, a quantified revenue forecast cannot be produced. What can be stated at the business level is the expected directionality under common intranasal steroid lifecycle phases:

Lifecycle pattern for branded nasal steroids

• Early phase: formulary expansion drives script growth; net price is higher but margin is reduced by incentives.
• Mid phase: PBM contracting stabilizes volume; net price compression begins as competitors adjust rebate structures.
• Late phase: generics and settlement-constrained launches compress net price; revenue declines unless AMBODRYL retains preferred status unusually long.

Key indicators that signal trajectory shifts

• PBM formulary changes: preferred or restricted tier movement
• Contracting outcomes: changes in rebate rates and client-specific thresholds
• Generic entry announcements: FDA approvals and launch dates for AB-rated products
• Litigation updates: outcomes that shorten or extend launch barriers
• Mix effects: retail vs mail and new patient vs continuation share

What patent litigation and settlement dynamics affect AMBODRYL’s financials?

Branded intranasal steroids often face:

• Paragraph IV challenges to Orange Book-listed patents
• Litigation over claim scope (composition/formulation/method-of-use)
• Settlements that either delay entry or allow earlier-than-patent expiry launch under specific terms

What to track in filings (high-impact items)

• Parties to the litigation (generic challengers vs NDA holder or patent owners)
• Patent asserted and claim construction outcomes
• Court timelines: preliminary injunction denials, claim construction decisions, final judgment
• Settlement terms: effective date of entry, carve-outs, licensing scope
• Design-around mechanisms: whether generic can enter via modified formulation or switching generic route

Without AMBODRYL’s litigation docket and Orange Book patent list, the patent-lifecycle schedule and financial effect cannot be mapped precisely.

How does FDA regulatory status shape AMBODRYL competition?

Intranasal products face regulatory scrutiny primarily through:

• FDA approvals and labeling scope
• Bioequivalence for generics and AB ratings
• REMS requirements (rare for nasal steroids)
• Changes in manufacturing or formulation supplements that may affect patent defenses

Generic competition pathway

When generics file Abbreviated New Drug Applications (ANDAs), they often rely on:

• Bioequivalence to the reference listed drug
• Carve-outs or Paragraph IV certifications tied to specific patents

If AMBODRYL’s patents cover formulation and not just active ingredient, generic workarounds can be harder, slowing entry and moderating price decline.

What generic entry risks exist for AMBODRYL?

Generic entry risks come from:

• Expiry of Orange Book-listed patents
• Successful Paragraph IV challenges and court defeats of asserted patents
• Settlement agreements that permit launch at a specified “allowed” date
• Launch delays caused by additional unexpired patents, manufacturing constraints, or regulatory holds

Revenue exposure mapping approach (business use)

To evaluate revenue exposure, map:

• Expected launch dates for AB-rated competitors
• Patent-specific barriers (drug substance vs formulation vs method-of-use)
• PBM substitution policies post-entry

Without AMBODRYL’s patent expiry and litigation schedule in the record here, exposure cannot be quantified.

Key takeaways

• AMBODRYL’s financial trajectory is primarily a function of formulary placement, PBM contracting intensity, and the timing of Orange Book-linked patent and exclusivity events.
• Brand resilience lasts only as long as AMBODRYL remains preferred and is protected from generic substitution by enforceable patents and/or settlements.
• Generic-entry waves typically trigger rapid net price compression, turning branded revenue from volume growth into decline unless AMBODRYL preserves preferred access.
• The decisive diligence targets for any revenue-risk assessment are Orange Book listings, Paragraph IV litigation, and settlement-effective entry dates, paired with PBM tier status changes.

FAQs

1. What market events most quickly reduce net revenue for branded intranasal steroids?
   PBM tier downgrades, prior authorization expansion, and generic launch approvals that change substitution incentives.

2. How do settlement agreements typically affect brand revenue after a Paragraph IV challenge?
   Settlements often delay entry to a defined date or restrict launch scope, extending the window for higher net prices and script continuity.

3. What Orange Book patent types create the biggest barriers to generic intranasal products?
   Formulation and method-of-use patents can be harder to design around than basic drug substance patents, depending on claim scope.

4. Do mail-order and retail channels change the competitive outcome for AMBODRYL?
   Yes. Mail-order PBM formularies and rebate structures often drive faster substitution when preferred tier contracts shift.

5. What commercial KPIs best indicate whether AMBODRYL is losing share to generics?
   New prescription growth, persistence/refill duration, tier placement changes, and net price compression versus category benchmarks.

References

No sources are provided in the prompt.